Q3 2023 EPS Estimates for Repligen Co. Reduced by Zacks Research (NASDAQ:RGEN)
Repligen Co. (NASDAQ:RGEN – Free Report) – Stock analysts at Zacks Research decreased their Q3 2023 EPS estimates for shares of Repligen in a note issued to investors on Thursday, October 26th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $0.18 per share for the quarter, down from their prior […]